Posted in M&A / Deals AbbVie enters world of pain in up to $715M deal with China’s Haisco April 13, 2026 BioSpace The licensing deal marks AbbVie’s first foray into new pain medicines, a space where Vertex currently enjoys a lead thanks to the NaV1.8 inhibitor Journavx. M&A / DealsPain & AnaesthesiaRead full story